

CLINICAL PHARMACOLOGY & THERAPEUTICS

VOLUME 80 NUMBER 3



PHARMACOKINETICS AND DRUG DISPOSITION

203 Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs

Graham Lappin, PhD, Wilhelm Kuhnz, PhD, Roeline Jochemsen, PhD, Johannes Kneer, PhD, Ajai Chaudhary, PhD, Berend Oosterhuis, PhD, Willem Jan Drijfhout, PhD, Malcolm Rowland, DSc, and R. Colin Garner, DSc, York and Manchester, United Kingdom, Berlin, Germany, Courbevoie, France, Basel, Switzerland, Indianapolis, Ind, and Zuidlaren, The Netherlands, Xceleron, York; Preclinical Development Pharmacokinetics, Schering, Berlin; Servier Research Group, Courbevoie; F. Hoffmann-La Roche, Basel; Eli Lilly, Indianapolis; Pharma Bio-Research Group, Zuidlaren; Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester

216 A positron emission tomography microdosing study with a potential anti-amyloid drug in healthy volunteers and patients with Alzheimer's disease

Martin Bauer, MD, Oliver Langer, PhD, Peter Dal-Bianco, MD, Rudolf Karch, PhD, Martin Brunner, MD, Aiman Abraham, Rupert Lanzenberger, MD, Andrea Hofmann, MD, Christian Joukhadar, MD, Paolo Carminati, PhD, Orlando Ghirardi, PhD, Paola Piovesan, PhD, Gianluigi Forloni, PhD, Mario E. Corrado, PhD, Nadège Lods, PhD, Robert Dudczak, MD, Eduard Auff, MD, Kurt Kletter, PhD, and Markus Müller, MD, Vienna, Austria, Rome and Milan, Italy, and Arzo, Switzerland, Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, and Departments of Neurology, Medical Computer Sciences, General Psychiatry, and Nuclear Medicine, Medical University of Vienna, Vienna; Sigma-Tau Industrie Farmaceutiche Riunite, Rome; Istituto di Ricerche Farmacologiche Mario Negri, Milan; CROSS, Arzo

Continued on page 2A

Clinical Pharmacology & Therapeutics (ISSN 0009-9236) is published monthly by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Business and Editorial Offices: 1600 John F. Kennedy Blvd, Suite 1800, Philadelphia, PA 19103-2899. Customer Service Office: 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Periodicals postage paid at New York, NY, and additional mailing offices. POSTMASTER: Send address changes to *Clinical Pharmacology & Therapeutics*, Elsevier Periodicals Customer Service, 6277 Sea Harbor Drive, Orlando, FL 32887-4800.

- 228 The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity**
Daniel Kurnik, MD, Alastair J. J. Wood, MD, and Grant R. Wilkinson, PhD, DSc, Nashville, Tenn, Departments of Medicine and Pharmacology, Division of Clinical Pharmacology, Vanderbilt University School of Medicine
- 235 Liver disease selectively modulates cytochrome P450-mediated metabolism**
Reginald F. Frye, PharmD, PhD, Nathalie K. Zgheib, MD, Gary R. Matzke, PharmD, Diego Chaves-Gnecco, MD, MPH, Mordechai Rabinovitz, MD, Obaid S. Shaikh, MD, and Robert A. Branch, MD, Gainesville, Fla, Pittsburgh, Pa, and Richmond, Va, Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville; Center for Clinical Pharmacology, Department of Medicine, University of Pittsburgh, Pittsburgh; College of Pharmacy, Virginia Commonwealth University, Richmond; UPMC Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh
- 246 Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients**
Patricia N. Sidharta, PharmD, Frank D. Wagner, MD, PhD, Holger Bohnemeier, MD, Arvid Jungnik, MD, Atef Halabi, MD, Stephan Krähenbühl, MD, PhD, Harbajan Chadha-Boreham, PhD, and Jasper Dingemanse, PharmD, PhD, Allschwil and Basel, Switzerland, and Berlin, Ulm, and Kiel, Germany, Actelion Pharmaceuticals Ltd, Allschwil; Charité Universitätsmedizin, Berlin; PHAROS GmbH, Ulm; IKP GmbH, Kiel; Departments of Clinical Pharmacology and Toxicology and Research, University Hospital Basel, Basel
- 257 Validation of incorporating flurbiprofen into the Pittsburgh cocktail**
Nathalie K. Zgheib, MD, Reginald F. Frye, PhD, Timothy S. Tracy, PhD, Marjorie Romkes, PhD, and Robert A. Branch, MD, Pittsburgh, Pa, Gainesville, Fla, and Minneapolis, Minn, Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh; Department of Pharmacy Practice, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis

Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s), publisher, or American Society for Clinical Pharmacology and Therapeutics, and the Editor(s), publisher, and American Society for Clinical Pharmacology and Therapeutics disclaim any responsibility or liability for such material. Neither the Editor(s) nor the publisher nor the American Society for Clinical Pharmacology and Therapeutics guarantees, warrants, or endorses any product or service advertised in this publication, nor do they guarantee any claim made by the manufacturer of such product or service.

PHARMACODYNAMICS AND DRUG ACTION

264 Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease

Giulia Renda, MD, PhD, Stefania Tacconelli, PhD, Marta L. Capone, PhD, Daniele Sacchetta, MD, Francesco Santarelli, MD, Maria G. Sciulli, PhD, Marco Zimarino, MD, Marilena Grana, MD, Elisabetta D'Amelio, PharmD, Maria Zurro, PharmD, Thomas S. Price, PhD, Carlo Patrono, MD, Raffaele De Caterina, MD, PhD, and Paola Patrignani, PhD, Chieti and Rome, Italy, and Philadelphia, Pa, Departments of Medicine and Clinical Sciences and Bioimaging and Center of Excellence on Aging, "G. d'Annunzio" University, School of Medicine, and "Gabriele d'Annunzio" University Foundation, Chieti; Department of Pharmacology, University of Rome "La Sapienza," 2nd School of Medicine, Rome; Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia

275 Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis

Carmine Cardillo, MD, Francesca Schinzari, MD, Nadia Mores, MD, Marco Mettimano, MD, Domenico Melina, MD, Angelo Zoli, MD, and Gianfranco Ferraccioli, MD, Rome, Italy, Department of Internal Medicine, Divisione di Terapia Medica, and Cattedra di Reumatologia, Complesso Integrato Columbus, and Istituto di Farmacologia, Università Cattolica del Sacro Cuore

PHARMACOGENETICS AND GENOMICS

282 Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations

Miki Nakajima, PhD, Tatsuki Fukami, MS, Hiroyuki Yamanaka, MS, Eriko Higashi, MS, Haruko Sakai, MS, Ryoko Yoshida, MS, Jun-Tack Kwon, MD, PhD, Howard L. McLeod, PhD, and Tsuyoshi Yokoi, PhD, Kanazawa, Japan, Chonan, South Korea, and St Louis, Mo, Department of Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa; Department of Clinical Pharmacology, Soonchunhyang University College of Medicine, Chonan; Department of Medicine, Washington University School of Medicine, St Louis

LETTERS TO THE EDITOR

298 Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?

A. David Rodrigues, PhD, Zheng Yang, PhD, Cliff Chen, MS, Devin Pray, MS, Sean Kim, PhD, and Michael Sinz, PhD, Princeton, NJ, and Wallingford, Conn

Continued on page 4A

301 Reply

Erik Eliasson, MD, PhD, and Mia Sandberg Lundblad, PhD, Stockholm, Sweden, and Bagsværd, Denmark

302 Imaging P-glycoprotein at the human blood-brain barrier

Eric J. F. Franssen, PhD, Gert Luurtsema, BSc, and Adriaan A. Lammertsma, PhD, Amsterdam, The Netherlands

303 Reply

Jashvant D. Unadkat, PhD, Jeanne M. Link, PhD, David A. Mankoff, MD, PhD, Mark Muzi, MS, and Ann C. Collier, MD, Seattle, Wash

NOTES OF THE AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS

305 A Message from the ASCPT Membership Committee Chairperson

READER SERVICES

8A New Guide to Authors

14A Information for Readers

297 Change of Address

Access to *Clinical Pharmacology & Therapeutics Online* is reserved for print subscribers!

Full-text access to *Clinical Pharmacology & Therapeutics Online* is available for all print subscribers. To activate your individual online subscription, please visit *Clinical Pharmacology & Therapeutics Online*, point your browser to <http://www.mosby.com/cpt>, follow the prompts to **activate your online access**, and follow the instructions. To activate your account, you will need your subscriber account number, which you can find on your mailing label (*note*: the number of digits in your subscriber account number varies from 6 to 10). See the example below in which the subscriber account number has been circled:

Sample mailing label

This is your subscription account number

*****3-DIGIT 013
SJ P1
FEB00 J009 C: 1 (1234567-89) U 05/00 Q: 1
J. H. DOE, MD
531 MAIN ST
CENTER CITY, NY 10001-0001

Personal subscriptions to *Clinical Pharmacology & Therapeutics Online* are for individual use only and may not be transferred. Use of *Clinical Pharmacology & Therapeutics Online* is subject to agreement to the terms and conditions as indicated online.